Standard clinicopathologic parameters, including prostate-specific antigen (PSA) and metrics of tumor volume at biopsy, are of limited utility in predicting outcomes for Grade Group 2 disease, and additional biomarkers are needed. This evidence concerns the gene KLK3 and neoplasm.